APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

12 1月 2026 07:00:01 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

05 1月 2026 07:00:00 条件 Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

03 12月 2025 17:05:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

25 11月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

12 11月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

05 11月 2025 07:00:01 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

30 10月 2025 07:05:00 条件 Nasdaq GlobeNewswire

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

20 10月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

16 10月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

27 8月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

31 7月 2025 07:05:08 条件 Nasdaq GlobeNewswire

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

28 7月 2025 19:19:32 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

24 7月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

15 7月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

01 7月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

06 6月 2025 09:15:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

04 6月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

07 5月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

06 5月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

30 4月 2025 07:00:00 条件 Nasdaq GlobeNewswire